Pharmacoeconomic analysis of rituximab and belimumab therapy in patients with systemic lupus erythematosus

Pharmacoeconomic analysis of rituximab and belimumab therapy in patients with systemic lupus erythematosus

The progressive course of systemic lupus erythematosus (SLE) with high activity and severe internal organs involvement requires the prescription of expensive biologic disease-modifying antirheumatic drugs (bDMARDs), rituximab (RTM) and belimumab (BLM), whose comparative clinical and economic efficac...

Full description

Bibliographic Details
Main Authors: D. A. Gerasimova, V. A. Gontarenko, E. V. Gerasimova, O. V. Zakharova, L. А. Lobuteva, T. V. Popkova, A. M. Lila
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2024-10-01
Series:Современная ревматология
Subjects:
clinical and economic analysis
systemic lupus erythematosus
belimumab
rituximab
cost-effectiveness analysis
Online Access:https://mrj.ima-press.net/mrj/article/view/1637

Internet

https://mrj.ima-press.net/mrj/article/view/1637

Similar Items